Interestingly, a recent study showed a significant increase of CD14+ monocytes and B cells in COVID-19 patients, which was shown to be associated with disease severity.20 Thus, our finding suggests that MSC treatment improved the outcomes of COVID-19 patients by modulating the immune composition of the peripheral blood of COVID-19 patients. This evidence concerns the gene CD14 and COVID-19.